These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1213 related articles for article (PubMed ID: 20713254)

  • 1. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
    Leroux-Roels G
    Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Principles of vaccine design-Lessons from nature.
    Zepp F
    Vaccine; 2010 Aug; 28 Suppl 3():C14-24. PubMed ID: 20713252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The importance of the second generation adjuvanted systems in "new" vaccines].
    Beran J
    Klin Mikrobiol Infekc Lek; 2008 Feb; 14(1):5-12. PubMed ID: 18327735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in vaccine research--unveiling the secret of vaccine adjuvants.
    de Veer M; Meeusen E
    Discov Med; 2011 Sep; 12(64):195-204. PubMed ID: 21955847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Starch microparticles as vaccine adjuvant.
    Rydell N; Stertman L; Sjöholm I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvants in perspective.
    Vogel FR
    Dev Biol Stand; 1998; 92():241-8. PubMed ID: 9554280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvants and autoimmunity.
    Israeli E; Agmon-Levin N; Blank M; Shoenfeld Y
    Lupus; 2009 Nov; 18(13):1217-25. PubMed ID: 19880572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving vaccine performance with adjuvants.
    Vogel FR
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S266-70. PubMed ID: 10875797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
    Lawson LB; Norton EB; Clements JD
    Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvants and delivery issues related to immunization: a survey of the recent patent literature.
    Mrsny RJ
    J Drug Target; 1998; 6(4):243-9. PubMed ID: 9894692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fish vaccine antigens produced or delivered by recombinant DNA technologies.
    Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G
    Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to link innate and adaptive immunity when designing vaccine adjuvants.
    Garlapati S; Facci M; Polewicz M; Strom S; Babiuk LA; Mutwiri G; Hancock RE; Elliott MR; Gerdts V
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):184-91. PubMed ID: 19042032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the innate immune response with improved vaccine adjuvants.
    Pashine A; Valiante NM; Ulmer JB
    Nat Med; 2005 Apr; 11(4 Suppl):S63-8. PubMed ID: 15812492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The perfect mix: recent progress in adjuvant research.
    Guy B
    Nat Rev Microbiol; 2007 Jul; 5(7):505-17. PubMed ID: 17558426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate immunity and new adjuvants.
    Mutwiri G; Gerdts V; Lopez M; Babiuk LA
    Rev Sci Tech; 2007 Apr; 26(1):147-56. PubMed ID: 17633299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.